Research programme: bone disorder therapeutics - Brookhaven National Laboratory/BioSurface Engineering Technologies
Alternative Names: B2A2; B2A2 K NSLatest Information Update: 16 Jul 2016
At a glance
- Originator BioSurface Engineering Technology; Brookhaven National Laboratory
- Class Peptides
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA (Parenteral, Implant)
- 17 Nov 2004 Preclinical trials in Bone disorders in USA (Parenteral)